Neoadjuvant hormonal ablative therapy before radical prostatectomy: A review. Is it indicated?

Journal of Urology

Volumn 164, Issue 5, 2000, Pages 1465-1472

  Scolieri, Michael J ^a   Altman, Andrew ^a   Resnick, Martin I ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Hormones; Neoadjuvant therapy; Prostate; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLEEDING; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LYMPH NODE METASTASIS; MALE; META ANALYSIS; MORBIDITY; OPERATION DURATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEMINAL VESICLE; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 0033786604     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67008-5     Document Type: Review

References (51)

1. Radical perineal prostatectomy: Oncological outcome during a 20-year period
2. Radical perineal prostatectomy subsequent to bilateral orchiectomy
3. Endocrine therapy in carcinoma of the prostate
4. New horizons in the surgical management of carcinoma of the prostate gland
5. Hormone control therapy as a preparation for radical perineal prostatectomy in advanced carcinoma of the prostate
6. Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: A retrospective study based upon 25 years of experience
7. Advanced cancer of the prostate
8. The use of estrogen therapy preliminary to radical perineal prostatoseminal vesiculectomy in carcinoma of the prostate
9. Non-resectable carcinoma of the prostate rendered resectable by endocrine therapy
10. Effects of neoadjuvant androgen deprivation therapy on prostatic cancer
11. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma
12. Neoadjuvant hormonal therapy: The Canadian experience
13. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer
14. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neoadjuvant hormone treatment
15. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer
16. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer
17. Neoadjuvant hormonal therapy before radical prostatectomy decrease the number of positive margins in stage T2 prostate cancer: Interim results of a prospective randomized trial
18. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study
19. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary
20. Neoadjuvant combined androgen deprivation therapy in locally confined prostatic carcinoma: 3-4 years of follow-up of a European randomized study
21. Radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer-24 month results
22. Hormonal treatment before radical prostatectomy: A 3-year followup
23. A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 months post-treatment PSA results
24. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
25. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: Results of a phase II study
26. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer
27. Time to normalization of serum testosterone after 3-month luteinizing hormone: Releasing hormone agonist administered in the neoadjuvant setting - Implications for dosing schedule and neoadjuvant study consideration
28. Supersensitive PSA-monitored neoadjuvant hormone treatment of clinically localized prostate cancer: Effects on positive margins, tumor detection and epithelial cells in bone marrow
29. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
30. Neoadjuvant hormonal deprivation before radical prostatectomy
31. Neoadjuvant hormonal deprivation before radical prostatectomy
32. A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment
33. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer
34. Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy
35. The role of neoadjuvant androgen deprivation prior to radical prostatectomy
36. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy
37. Prognostic implications of a positive apical margin in radical prostatectomy specimens
38. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology
39. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer
40. Pathological changes in prostate lesions after androgen manipulation
41. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma
42. Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension
43. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy
44. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma
45. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer
46. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer - Initial results
47. Neoadjuvant GnRH-agonist treatment (triptorelin and cyproterone acetate for flare protection) and total prostatectomy
48. Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor
49. Prognostic significance of positive surgical margins in radical prostatectomy specimens
50. Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen. Rationale for seminal vesicle biopsies
51. Endocrine treatment prior to radical retropubic prostatectomy in patients with T3 prostate cancer: A retrospective study of 22 patients